相关实验视频
Updated: Jun 12, 2025

10:10
Quantifying Cognitive Decrements Caused by Cranial Radiotherapy
Published on: October 18, 2011
12.7K
自我报告的与癌症相关的认知障碍与扰乱的神经传递通路有关
Kate R Oppegaard1, Yvette P Conley2, Steven Paul3
1Dana-Farber Cancer Institute, University of Massachusetts, Boston, MA, USA.
Journal of neural transmission (Vienna, Austria : 1996)
|September 26, 2024
概括
这项研究揭示了在接受化疗的患者中与癌症相关的认知障碍 (CRCI) 相关的七种神经传递途径. 这些发现为开发有效的干预措施来管理CRCI提供了新的目标.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 与癌症相关的认知障碍 (CRCI) 影响了大量癌症患者,但其潜在机制仍然不太清楚.
- 现有的知识差距阻碍了针对CRCI开发有针对性的干预措施.
研究的目的:
- 用数据驱动方法识别与不同癌症相关认知障碍 (CRCI) 配置文件相关的扰乱生物途径.
- 研究癌症患者在化疗期间经历的认知变化的分子基础.
主要方法:
- 使用注意力功能指数对508名接受化疗的癌症患者进行认知功能的纵向评估.
- 基于潜形状分析,对CRCI概况高或低的患者进行亚组分析.
- 基因表达分析 (RNA测序和微阵列) 与使用京都基因和基因组百科全书 (KEGG) 数据库的途径影响分析相结合.
主要成果:
- 在患有高CRCI的患者中,七个关键的神经传递通路被确定为明显扰乱.
- 这些途径包括谷氨酸突触,GABA突触,多巴胺突触,血清突触,长期抑郁,胆突触和逆行性内分泌卡纳比诺इड信号传递.
- 这些发现在RNA测序和微阵列数据集中一致.
结论:
- 这项研究首次确定了各种癌症 (乳腺癌,胃肠道癌,妇科癌,肺癌) 和七种特定的神经传递通路的患者自我报告的CRCI之间的关联.
- 已识别的途径代表了未来旨在缓解CRCI的治疗干预措施的潜在机制性目标.
相关概念视频
Psychoneuroimmunology: Diabetes and Cancer
25
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
25
Role of Neurotransmitters in Memory
478
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
478
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Negative and Cognitive Symptoms of Schizophrenia
46
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
46
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
107
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
107

